Massimo Santoro Selected Research

Multiple Endocrine Neoplasia Type 2b (MEN 3)

12/2009	Targeting the RET pathway in thyroid cancer.
6/2006	The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
12/2002	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
6/2002	Molecular mechanisms of RET activation in human cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Massimo Santoro Research Topics

Disease

60	Neoplasms (Cancer) 01/2022 - 02/2002
45	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 06/2002
22	Papillary Thyroid Cancer 01/2020 - 06/2002
11	Carcinoma (Carcinomatosis) 06/2014 - 01/2002
7	Papillary Carcinoma 03/2010 - 06/2002
6	Myotonic Dystrophy (Dystrophia Myotonica) 09/2020 - 10/2010
6	Carcinogenesis 01/2018 - 02/2002
6	Multiple Endocrine Neoplasia Type 2a (MEN 2) 08/2013 - 06/2002
5	Stroke (Strokes) 05/2022 - 12/2017
4	Pain (Aches) 05/2022 - 08/2017
4	Neoplasm Metastasis (Metastasis) 10/2021 - 03/2006
4	Anaplastic Thyroid Carcinoma 01/2018 - 08/2005
4	Inflammation (Inflammations) 01/2018 - 10/2002
4	medullary Thyroid cancer 10/2014 - 04/2003
4	Adenoma (Adenomas) 11/2011 - 01/2002
4	Multiple Endocrine Neoplasia Type 2b (MEN 3) 12/2009 - 06/2002
3	Multiple Sclerosis 09/2021 - 01/2018
3	Leukemia 01/2020 - 06/2002
3	Follicular Adenocarcinoma 01/2019 - 09/2004
3	Disease Progression 01/2019 - 01/2012
3	Neuroblastoma 02/2015 - 06/2002
2	Adenocarcinoma of Lung 10/2021 - 03/2014
2	Neuralgia (Stump Neuralgia) 10/2021 - 12/2017
2	Colorectal Neoplasms (Colorectal Cancer) 04/2021 - 10/2010
2	Friedreich Ataxia (Friedreich's Ataxia) 01/2021 - 10/2020
2	Liposarcoma 12/2018 - 11/2003
2	Dystonia musculorum deformans type 1 01/2018 - 01/2017
2	Dystonia (Limb Dystonia) 01/2018 - 01/2017
2	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 08/2015 - 12/2010
2	Lung Neoplasms (Lung Cancer) 01/2012 - 10/2010
2	Wounds and Injuries (Trauma) 01/2011 - 03/2009
2	Sandhoff Disease (Sandhoff's Disease) 12/2010 - 05/2007
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2010 - 09/2005
1	Postoperative Pain 10/2021
1	Knee Osteoarthritis 10/2021
1	Autoimmune Diseases (Autoimmune Disease) 09/2021

Drug/Important Bio-Agent (IBA)

25	Phosphotransferases (Kinase)IBA 01/2022 - 02/2002
22	Proteins (Proteins, Gene)FDA Link 09/2021 - 05/2002
17	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 02/2002
12	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 06/2002
8	Biological ProductsIBA 01/2015 - 07/2003
7	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2017 - 06/2002
5	LigandsIBA 01/2018 - 08/2004
5	Messenger RNA (mRNA)IBA 05/2014 - 06/2006
5	vandetanib (ZD6474)IBA 01/2012 - 12/2002
4	Biomarkers (Surrogate Marker)IBA 05/2022 - 11/2020
4	Brain-Derived Neurotrophic Factor (BDNF)IBA 11/2020 - 12/2017
4	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 09/2020 - 05/2005
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 11/2007
4	Tyrosine Kinase InhibitorsIBA 01/2017 - 12/2002
3	Long Noncoding RNAIBA 10/2021 - 01/2020
3	RNA (Ribonucleic Acid)IBA 09/2020 - 06/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2006
3	HMGA2 ProteinIBA 12/2018 - 11/2003
3	Adenosine Triphosphate (ATP)IBA 05/2013 - 12/2009
3	Chemokine ReceptorsIBA 01/2012 - 08/2004
3	Superoxide DismutaseIBA 01/2011 - 03/2009
3	ErbB Receptors (EGF Receptor)IBA 10/2010 - 12/2002
3	Sorafenib (BAY 43-9006)FDA Link 10/2010 - 03/2006
3	OsteopontinIBA 11/2005 - 09/2005
2	AntioxidantsIBA 05/2022 - 02/2015
2	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2022 - 01/2018
2	pyrimidineIBA 01/2022 - 04/2003
2	Antisense RNA (Anti-Sense RNA)IBA 10/2021 - 01/2020
2	TropomyosinIBA 04/2021 - 01/2019
2	Proto-Oncogene Proteins c-retIBA 01/2020 - 03/2009
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 10/2012
2	Cholinergic Agents (Cholinergics)IBA 01/2018 - 01/2017
2	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2018 - 01/2017
2	Dopamine (Intropin)FDA LinkGeneric 01/2017 - 02/2015
2	Protein Kinases (Protein Kinase)IBA 05/2016 - 01/2006
2	Levodopa (L Dopa)FDA LinkGeneric 02/2015 - 02/2007
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 07/2014 - 10/2002
2	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 08/2013 - 07/2007
2	Small Interfering RNA (siRNA)IBA 01/2012 - 01/2008
2	EnzymesIBA 12/2010 - 03/2009
2	AgarIBA 10/2010 - 05/2002
2	Mitogen-Activated Protein KinasesIBA 10/2010 - 11/2005
2	Monoclonal AntibodiesIBA 05/2010 - 06/2002
2	Cytostatic AgentsIBA 01/2010 - 12/2009
2	Epidermal Growth Factor (EGF)IBA 10/2008 - 12/2002
2	ParaffinIBA 08/2008 - 09/2004
2	Chemokine CXCL12IBA 12/2007 - 08/2004
2	Urea (Carbamide)FDA LinkGeneric 07/2007 - 03/2006
2	Growth Factor ReceptorsIBA 01/2007 - 01/2006
2	matrigelIBA 11/2005 - 09/2005
2	CytokinesIBA 11/2005 - 07/2003
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 09/2005 - 06/2003
2	Cyclin-Dependent Kinase Inhibitor p27IBA 06/2004 - 10/2002
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 06/2003 - 10/2002
2	Complementary DNA (cDNA)IBA 02/2003 - 05/2002
1	Untranslated RNA (Noncoding RNA)IBA 10/2021
1	NucleotidesIBA 09/2021

Therapy/Procedure

12	Therapeutics 09/2021 - 10/2002
4	Thyroidectomy 05/2014 - 03/2006
3	Lasers (Laser) 01/2020 - 06/2002
3	Drug Therapy (Chemotherapy) 01/2018 - 12/2007
3	Radiotherapy 01/2018 - 12/2007
2	Oral Administration 01/2020 - 02/2015
1	Knee Replacement Arthroplasty (Total Knee Replacement) 10/2021